BLOOD

Scope & Guideline

Exploring the Depths of Blood Science.

Introduction

Welcome to your portal for understanding BLOOD, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0006-4971
PublisherAMER SOC HEMATOLOGY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1946 to 2024
AbbreviationBLOOD / Blood
Frequency52 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2021 L ST NW, SUITE 900, WASHINGTON, DC 20036

Aims and Scopes

The journal 'BLOOD' focuses on advancing the field of hematology through innovative research that encompasses various aspects of blood disorders, including their biology, diagnosis, treatment, and patient management.
  1. Hematologic Malignancies:
    A core focus of the journal is on hematologic cancers such as leukemia, lymphoma, and myeloma, including studies on their molecular mechanisms, therapeutic strategies, and clinical outcomes.
  2. Transfusion Medicine and Hemostasis:
    Research related to blood transfusion practices, coagulation disorders, and the management of bleeding disorders is prominently featured, emphasizing both clinical and laboratory aspects.
  3. Genomics and Precision Medicine:
    The journal publishes studies on the genetic basis of blood disorders and the application of genomic technologies to personalize treatment approaches.
  4. Immunotherapy and Novel Therapeutics:
    There is a significant focus on immunotherapeutic strategies, including CAR T-cell therapies and monoclonal antibodies, aimed at treating various hematologic malignancies.
  5. Patient-Centered Care and Quality of Life:
    Research addressing the psychosocial aspects of hematologic diseases, including patient-reported outcomes and the impact of treatment on quality of life, is increasingly emphasized.
  6. Clinical Trials and Real-World Evidence:
    The journal highlights findings from clinical trials as well as real-world studies that provide insights into treatment effectiveness and safety in diverse populations.
The journal 'BLOOD' has witnessed a notable evolution in its scope, with emerging themes reflecting the latest advancements in hematologic research and clinical practice. These trends highlight the journal's commitment to addressing contemporary challenges in hematology.
  1. CAR T-Cell Therapy:
    There is a significant increase in research related to CAR T-cell therapies, including their development, efficacy, and management of associated toxicities, reflecting the growing importance of this treatment modality in hematologic malignancies.
  2. Genetic and Molecular Profiling:
    Studies focusing on genetic mutations, epigenetic changes, and their implications for disease progression and treatment response are becoming increasingly prevalent, emphasizing the role of precision medicine in hematology.
  3. Real-World Evidence and Health Economics:
    The journal is increasingly publishing articles that analyze real-world data to evaluate treatment outcomes and healthcare costs, highlighting the importance of pragmatic approaches in clinical decision-making.
  4. Immunotherapy Combinations:
    Emerging research on combining immunotherapies with other treatment modalities, such as targeted therapies and traditional chemotherapy, is gaining momentum, indicating a shift towards multi-faceted treatment strategies.
  5. Patient-Centered Research:
    An emphasis on patient-reported outcomes, quality of life assessments, and studies addressing the psychosocial aspects of hematologic diseases is becoming more pronounced, reflecting a holistic approach to patient care.

Declining or Waning

While the journal 'BLOOD' continues to explore a wide array of topics within hematology, certain areas have seen a decrease in focus or publication frequency over the years, reflecting evolving research priorities and advancements in the field.
  1. Traditional Chemotherapy Approaches:
    There is a declining emphasis on classical chemotherapy regimens for hematologic malignancies as newer targeted therapies and immunotherapies gain prominence.
  2. Basic Hematology Research:
    Research focused solely on basic hematology without immediate clinical application appears to be waning, as the journal increasingly prioritizes translational and clinical studies.
  3. Epidemiological Studies:
    While still relevant, the volume of purely epidemiological studies on blood disorders has decreased, with a shift towards more integrated approaches that combine clinical outcomes with genomic and molecular data.
  4. Single-Agent Therapy Studies:
    The focus on studies evaluating the efficacy of single-agent therapies has diminished, as combination therapies are recognized for their enhanced effectiveness in treating complex hematologic conditions.
  5. Niche Hematologic Disorders:
    Research on less common hematologic conditions may be receiving less attention in favor of more prevalent disorders and broader therapeutic strategies.

Similar Journals

HemaSphere

Transforming knowledge into patient care advancements.
Publisher: WILEYISSN: Frequency: 12 issues/year

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

HAEMATOLOGICA

Leading the Way in Hematological Innovation
Publisher: FERRATA STORTI FOUNDATIONISSN: 0390-6078Frequency: 12 issues/year

HAEMATOLOGICA, published by FERRATA STORTI FOUNDATION, is a prestigious journal in the field of hematology, recognized for its high impact and contribution to advancing research in this critical area of medicine. With an impressive Q1 ranking in the 2023 category of Hematology and a notable Scopus rank of #12 out of 137, the journal serves as an essential platform for disseminating innovative studies, clinical trials, and comprehensive reviews from 1947 to 2024. Based in Italy, with a commitment to quality and academic integrity, HAEMATOLOGICA fosters collaboration among researchers, practitioners, and students interested in the latest developments and methodologies within hematological science. Although it does not offer open access, the journal ensures that valuable insights are accessible through institutional subscriptions, emphasizing its role in shaping the future of hematologic research.

Cancer Discovery

Bridging Discovery and Treatment in Cancer Care
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2159-8274Frequency: 12 issues/year

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.

Journal of Blood Medicine

Exploring Frontiers: Where Blood Medicine Meets Cutting-edge Science
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Advancing the Science of Blood Health
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

TRANSFUSION MEDICINE AND HEMOTHERAPY

Elevating the standards of hemotherapy and transfusion practices.
Publisher: KARGERISSN: 1660-3796Frequency: 6 issues/year

TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.

Therapeutic Advances in Hematology

Bridging clinical insights with laboratory innovations.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

EUROPEAN JOURNAL OF HAEMATOLOGY

Transforming Hematology Through Rigorous Research
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Hematology-American Society of Hematology Education Program

Empowering Knowledge in Blood Disorders
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Blood Transfusion

Innovating Hematology for Better Patient Outcomes.
Publisher: SIMTIPRO SRLISSN: 1723-2007Frequency: 6 issues/year

Blood Transfusion is a leading journal in the fields of Hematology, Immunology, and Medicine, published by SIMTIPRO SRL in Italy. With its ISSN 1723-2007, the journal has established a significant presence in the academic community, as evidenced by its positioning within the Q2 category in Hematology and Medicine (miscellaneous) and Q3 in Immunology and Allergy for 2023. Notably, it ranks #38 out of 137 in the Hematology category, showcasing its impactful contributions to research and practice. Operating under a traditional publishing model, this journal provides valuable insights into advances in blood transfusion science, ultimately aimed at enhancing patient care and outcomes. Spanning from 2003 to 2024, the scope of Blood Transfusion covers a wide range of topics related to hematological and immunological research, making it an essential resource for researchers, healthcare professionals, and students engaged in these critical fields.